ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care. In part 2 of an interview with The American ...

CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...

Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

Objectives: The burden of a new cancer diagnosis on state Medicaid programs is not well understood. Our study aimed to (1) ...

Eligibility estimates contract from ~13.3 million with obesity/overweight to ~3.8 million Bridge-eligible Part D enrollees after excluding diabetes, OSA, MASH, and current GLP‑1 users. Modeled ...

Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer. Patients from racially and ethnically ...

Pediatric cancer hospitalizations are approximately 2.5 times costlier than adult admissions, reflecting longer stays and ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...